Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.84 USD | +3.65% | -4.05% | -54.74% |
04-23 | Top Premarket Decliners | MT |
04-01 | T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 22.3M 30.49M | Sales 2023 | 7.19M 9.83M | Capitalization | 25.42M 34.74M |
---|---|---|---|---|---|
Net income 2022 | -62M -84.75M | Net income 2023 | -50M -68.34M | EV / Sales 2022 | 2.66 x |
Net Debt 2022 | 48.89M 66.83M | Net Debt 2023 | 33.81M 46.21M | EV / Sales 2023 | 8.23 x |
P/E ratio 2022 |
-0.12
x | P/E ratio 2023 |
-0.33
x | Employees | 113 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.08% |
Latest transcript on T2 Biosystems, Inc.
1 day | +3.65% | ||
1 week | -4.05% | ||
Current month | -5.33% | ||
1 month | -0.70% | ||
3 months | -32.70% | ||
6 months | -49.38% | ||
Current year | -54.74% |
Managers | Title | Age | Since |
---|---|---|---|
John Sperzel
CEO | Chief Executive Officer | 60 | 20-01-07 |
John Sprague
DFI | Director of Finance/CFO | 65 | 18-01-29 |
Roger Smith
CTO | Chief Tech/Sci/R&D Officer | 59 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Elsbree
BRD | Director/Board Member | 76 | 14-06-30 |
Seymour Liebman
BRD | Director/Board Member | 74 | 16-09-20 |
Robin Toft
BRD | Director/Board Member | 63 | 20-06-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.84 | +3.65% | 140,888 |
24-04-25 | 2.74 | -0.72% | 412,422 |
24-04-24 | 2.76 | +1.47% | 330,290 |
24-04-23 | 2.72 | -13.92% | 359,187 |
24-04-22 | 3.16 | +6.76% | 1,363,736 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-54.74% | 24.97M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- TTOO Stock